Efficacy, Safety, and Dose Response of STS01, a Topical Controlled Release Nanoparticle Formulation (Dithranol/Prosilic), in Adults with Mild to Moderate Patchy Alopecia Areata: A Randomized, Double-Blind, Multicenter, Phase 2 Trial
April 2026
in “
medRxiv
”
New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide →
Preprint — not peer reviewed. This was posted to a preprint server or data repository. It has not been through a journal's review process, and its findings may change or not hold up.
Studysummary In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer